TRINITY BIOTECH PLC-SPON ADR (TRIB) Fundamental Analysis & Valuation

NASDAQ:TRIB • US8964385046

0.7318 USD
+0.03 (+4.54%)
At close: Mar 5, 2026
0.7483 USD
+0.02 (+2.25%)
After Hours: 3/5/2026, 8:24:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TRIB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to TRIB. TRIB was compared to 184 industry peers in the Health Care Equipment & Supplies industry. TRIB may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TRIB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. TRIB Profitability Analysis

1.1 Basic Checks

  • TRIB had negative earnings in the past year.
  • In the past year TRIB has reported a negative cash flow from operations.
  • TRIB had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: TRIB reported negative operating cash flow in multiple years.
TRIB Yearly Net Income VS EBIT VS OCF VS FCFTRIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

  • TRIB's Return On Assets of -31.91% is on the low side compared to the rest of the industry. TRIB is outperformed by 60.33% of its industry peers.
Industry RankSector Rank
ROA -31.91%
ROE N/A
ROIC N/A
ROA(3y)-38.57%
ROA(5y)-23.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRIB Yearly ROA, ROE, ROICTRIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

  • TRIB has a worse Gross Margin (34.83%) than 73.91% of its industry peers.
  • TRIB's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TRIB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.46%
GM growth 5Y-3.74%
TRIB Yearly Profit, Operating, Gross MarginsTRIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. TRIB Health Analysis

2.1 Basic Checks

  • TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TRIB remains at a similar level compared to 1 year ago.
  • TRIB has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, TRIB has an improved debt to assets ratio.
TRIB Yearly Shares OutstandingTRIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
TRIB Yearly Total Debt VS Total AssetsTRIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -1.16, we must say that TRIB is in the distress zone and has some risk of bankruptcy.
  • TRIB has a Altman-Z score (-1.16) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.16
ROIC/WACCN/A
WACC7.11%
TRIB Yearly LT Debt VS Equity VS FCFTRIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • TRIB has a Current Ratio of 1.05. This is a normal value and indicates that TRIB is financially healthy and should not expect problems in meeting its short term obligations.
  • TRIB's Current ratio of 1.05 is on the low side compared to the rest of the industry. TRIB is outperformed by 87.50% of its industry peers.
  • A Quick Ratio of 0.41 indicates that TRIB may have some problems paying its short term obligations.
  • TRIB has a worse Quick ratio (0.41) than 92.93% of its industry peers.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 0.41
TRIB Yearly Current Assets VS Current LiabilitesTRIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TRIB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 41.07% over the past year.
  • TRIB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.31%.
  • TRIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.41% yearly.
EPS 1Y (TTM)41.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.04%
Revenue 1Y (TTM)8.31%
Revenue growth 3Y-8.8%
Revenue growth 5Y-7.41%
Sales Q2Q%16.15%

3.2 Future

  • TRIB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.68% yearly.
  • Based on estimates for the next years, TRIB will show a quite strong growth in Revenue. The Revenue will grow by 11.62% on average per year.
EPS Next Y65.8%
EPS Next 2Y34.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.13%
Revenue Next 2Y11.62%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TRIB Yearly Revenue VS EstimatesTRIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
TRIB Yearly EPS VS EstimatesTRIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. TRIB Valuation Analysis

4.1 Price/Earnings Ratio

  • TRIB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TRIB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRIB Price Earnings VS Forward Price EarningsTRIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRIB Per share dataTRIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • TRIB's earnings are expected to grow with 34.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.68%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TRIB Dividend Analysis

5.1 Amount

  • TRIB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRIB Fundamentals: All Metrics, Ratios and Statistics

TRINITY BIOTECH PLC-SPON ADR

NASDAQ:TRIB (3/5/2026, 8:24:05 PM)

After market: 0.7483 +0.02 (+2.25%)

0.7318

+0.03 (+4.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)04-03
Inst Owners24.88%
Inst Owner Change-68.6%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.69M
Revenue(TTM)61.55M
Net Income(TTM)-31.79M
Analysts85.71
Price TargetN/A
Short Float %67.2%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.68
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS3.29
BVpS-2.65
TBVpS-5.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.91%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.83%
FCFM N/A
ROA(3y)-38.57%
ROA(5y)-23.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.46%
GM growth 5Y-3.74%
F-Score2
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 405.1%
Cap/Sales 15.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 0.41
Altman-Z -1.16
F-Score2
WACC7.11%
ROIC/WACCN/A
Cap/Depr(3y)316%
Cap/Depr(5y)319.23%
Cap/Sales(3y)10.22%
Cap/Sales(5y)10.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.04%
EPS Next Y65.8%
EPS Next 2Y34.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.31%
Revenue growth 3Y-8.8%
Revenue growth 5Y-7.41%
Sales Q2Q%16.15%
Revenue Next Year10.13%
Revenue Next 2Y11.62%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-72.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.1%
OCF growth 3YN/A
OCF growth 5YN/A

TRINITY BIOTECH PLC-SPON ADR / TRIB FAQ

What is the fundamental rating for TRIB stock?

ChartMill assigns a fundamental rating of 1 / 10 to TRIB.


Can you provide the valuation status for TRINITY BIOTECH PLC-SPON ADR?

ChartMill assigns a valuation rating of 1 / 10 to TRINITY BIOTECH PLC-SPON ADR (TRIB). This can be considered as Overvalued.


Can you provide the profitability details for TRINITY BIOTECH PLC-SPON ADR?

TRINITY BIOTECH PLC-SPON ADR (TRIB) has a profitability rating of 0 / 10.


Is the dividend of TRINITY BIOTECH PLC-SPON ADR sustainable?

The dividend rating of TRINITY BIOTECH PLC-SPON ADR (TRIB) is 0 / 10 and the dividend payout ratio is 0%.